参考文献:
1.Jacenollo, P.(1992). Niacin versus niacinamide
2. Knip M, DouekIF, Moore WP etal. (2000). "Safety of high-dose nicotinamide: a review".Diabetologia 43 (11): 1337–45. doi:10.1007/s001250051536. PMID 11126400.
3. Belenky P;Bogan KL; Brenner C (2007). "NAD+ metabolism in health and disease".Trends Biochem. Sci. 32 (1): 12–9. doi:10.1016/j.tibs.2006.11.006. PMID17161604. Retrieved 2007-12-23.
4. Niren NM(2006). "Pharmacologic doses of nicotinamide in the treatment ofinflammatory skin conditions: a review". Cutis 77 (1 Suppl): 11–6. PMID16871774.
5. Shalita AR,Smith JG, Parish LC, Sofman MS, Chalker DK (June 1995). "Topicalnicotinamide compared with clindamycin gel in the treatment of inflammatoryacne vulgaris". International Journal of Dermatology 34 (6): 434–7.doi:10.1111/j.1365-4362.1995.tb04449.x. PMID 7657446.
6. Hakozaki T,Minwalla L, Zhuang J et al. (July 2002). "The effect of niacinamide onreducing cutaneous pigmentation and suppression of melanosome transfer".Br. J. Dermatol. 147 (1): 20–31. doi:10.1046/j.1365-2133.2002.04834.x. PMID12100180.
7. Navarrete-SolísJ, Castanedo-Cázares JP, Torres-Álvarez B et al. (July 2011). "ADouble-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone4% in the Treatment of Melasma". Dermatol Res Pract. 2011 (379173): 1.doi:10.1155/2011/379173. PMC 3142702. PMID 21822427.